NYSE American: IGC

Investor Relations

Committed to transparency and the advancement of next-generation therapies for neurodegenerative diseases through rigorous science and AI-driven innovation.

alzheimer igc pharma
IGC Pharma’s Advisor and Inventor of Drug Candidate TGR-63 Receives Award
Read More →
artificial intelligence igc pharma
IGC Pharma to Present at LD Micro Invitational XIII
Read More →
alzheimer igc pharma
IGC PHARMA to Present at the Planet MicroCap Showcase VEGAS 2023
Read More →
igc pharma
Investor Summit March 2023
Read More →
healthcare summit tgr-63 biotech igc pharma
IGC Announces Rebranding Changes Name to IGC Pharma Inc
Read More →
igc pharma
IGC Reports Financial Results for Third Fiscal Quarter Ended Dec. 31, 2022
Read More →
healthcare summit tgr-63 biotech igc pharma
IGC to be Featured in Feb. 10 Radius Research Investor Webinar
Read More →
alzheimer igc pharma
IGC Receives No objection letter from Health Canada JAN 4. 3023
Read More →
healthcare summit tgr-63 biotech igc pharma
IGC Applauds Signing of Bipartisan Medical Marijuana and Cannabidiol Research Expansion Act
Read More →
clincloud
IGC Commences Phase 2 Clinical Trials Evaluating Drug Candidate IGC-AD1 for the Treatment of Agitation in Dementia From Alzheimer Disease
Read More →
igc pharma
IGC to Present at the RHK 2022 Disruptive Growth Conference
Read More →
igc pharma
IGC Reports Financial Results for the Quarter Ended September 30, 2022
Read More →
igc-ad1 igc pharma
IGC Announces Issuance of Second Patent for the Treatment of Alzheimer’s Using THC
Read More →
igc pharma
IGC Announces Results of its 2022 Annual Stockholders Meeting
Read More →
igc pharma
IGC Reports Financial Results for the Quarter Ended June 30, 2022
Read More →
igc pharma
IGC Reports Financial Results for Fiscal Year Ended March 31, 2022
Read More →